• EuroEyes annual report for fiscal year ended Dec. 31, 2025 flagged record revenue growth, driven by stronger demand for presbyopia treatments across core European markets.
• Switzerland expansion moved into execution with acquisition of eight clinics completed on Oct. 13, 2025; integration and rebranding underway with EBITDA breakeven targeted by mid-fiscal 2026.
• Netherlands deal advanced with agreement to buy FYEO, a 13-clinic refractive surgery provider; closing expected by mid-fiscal 2026, subject to shareholder approval.
• Operating momentum centered on Germany and UK as main growth engines, supported by presbyopia mix shift and a pickup in myopia procedures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euroeyes International Eye Clinic Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260429-12132945), on April 29, 2026, and is solely responsible for the information contained therein.